Mauna Kea Technologies Announces the Terms of its Financing Under its Safeguard Plan

Regulatory News:

Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today specifies the terms of its proposed capital increase (the "Capital Increase") as part of its safeguard plan, which was approved by a majority of the classes of affected parties as announced on October 6.

The Capital Increase, for a total amount between €5 million and €8 million, will be carried out through a private placement of shares with attached warrants ("ABSA") to institutional investors, family offices, and business angels known for their expertise and long-term investment approach in the healthcare and MedTech sectors.

- Subscription Price: The issue price (the "Issue Price") will be set by the Board of Directors on the date of the Court's decision to adopt the safeguard plan (the "Pricing Date"), which is expected to occur in the first half of November. It will be equal to the lower of the following two amounts: (i) the volume-weighted average price (VWAP) of the 10 trading days preceding the Pricing Date, or (ii) €0.12. This structure ensures a transaction with no discount if the average price is less than or equal to €0.12.

- Warrants (BSA): To involve all shareholders in the future success of the company:

• New Investors: One BSA will be attached to each new share subscribed.
• Existing Shareholders: All current shareholders will be granted one (1) free BSA for every ten (10) shares held in their securities accounts on the Pricing Date, expected in the first half of November.
• BSA terms: Each BSA will entitle the holder to subscribe for one (1) new share for a period of 5 years at an exercise price corresponding to 125% of the Issue Price. An application will be made to list the BSAs on Euronext Growth.

The Company has received a firm subscription commitment totaling €2.7 million from a well-known investor in the healthcare sector. This firm commitment represents more than half of the minimum target for the Capital Increase, and is supplemented by indications of interest from about twenty other specialized investors (business angels, family offices, and institutional investors), already allowing the minimum target of €5 million to be exceeded. Mr. Sacha Loiseau, Chairman and CEO, has also committed to participating in the Capital Increase. The Company will focus on completing the order book in the coming weeks.